ClinicalTrials.gg
CompletedNCT05307692Updated Apr 27, 2025Results posted

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

A Phase 2 interventional study of Seltorexant and Placebo in Alzheimer Disease, sponsored by Janssen Research & Development, LLC. Completed at 25 sites in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Alzheimer Disease by Johnson & Johnson — 1 open to participants now, 2 under way, none of them phase 3. Alzheimer Disease · Johnson & Johnson.

Enrollment
30th of 50
88 · median 108
Started
2022
the only one that year
Phase 2
6 of 61
1 open now
Registered
59th of 61
by date

Among the 61 studies in Alzheimer Disease by Johnson & Johnson, this one is the 30th largest by enrollment of the 50 interventional ones that give a count, is the only one that started in 2022, is one of 6 in phase 2, and was the 59th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 61 studies in Alzheimer Disease by Johnson & Johnson is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Alzheimer Disease by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with probable Alzheimer's Disease (AD) with clinically significant agitation/aggression.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has received a diagnosis of probable Alzheimer Disease (AD) (-5 [DSM-5]) with the following characteristics at screening: Clinical Dementia Rating (CDR) global score greater than or equal to (>=) 1; (MMSE) total score of 10 to 24 (inclusive)
  • Participant meets the criteria of a syndrome diagnosis of agitation based on International Psychogeriatric Association (IPA) consensus clinical and research definition of agitation in cognitive disorders for at least 2 weeks before screening
  • Participant meets the criteria of Neuropsychiatric Inventory (NPI-12) Agitation/Aggression (A/A) domain score >= 4 with frequency score >= 2 at screening and baseline with no more than 35 percent (%) of improvement in NPI-12 A/A domain score from the screening to baseline assessments
  • Female participants must be before study entry (amenorrhea for at least 12 months)
  • (BMI) within the range 18-40 kilograms per square meter (kg/m\^2) (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Participant fulfils diagnostic criteria for non-Alzheimer's Dementia: example, Frontotemporal Dementia (FTD), Diffuse Lewy Body Dementia (DLBD), and post-stroke dementia, based on clinical history. (Participants may be included with mixed AD/vascular dementia)
  • Participant has a acute illness within 7 days prior to study intervention administration
  • Participants with a history of delirium within 30 days prior to or during screening
  • Participant with a cause of agitation that is not secondary to dementia (such as pain) or significant history of aggression prior to dementia based on investigator judgment
  • Participants who are not stable on concomitant medications or take prohibited medications
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Seltorexant

    Participants will receive single oral dose of seltorexant 20 milligrams (mg) tablet once daily from Day 1 to Day 42.

    Drug: Seltorexant

  • Placebo comparator
    Placebo

    Participants will receive single oral dose of matching placebo tablet once daily from Day 1 to Day 42.

    Drug: Placebo

Interventions

  • Seltorexant 20 mg will be administered orally as a tablet.

    Also known as: JNJ-42847922

  • DrugPlacebo

    Matching placebo will be administered orally as a tablet.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Neuropsychiatric Inventory Clinician Version (NPI-C) Sum of Agitation and Aggression Domain Scores (NPI-C A+A) at Day 43: Analyzed Under Estimand 1

    The NPI-12, measure of psychobehavioral disturbances assessed frequency and severity of disturbances in 12 domains, based on a caregiver interview. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being product of frequency and severity scores, such that each domain was scored from 1 to 12. The NPI-12 total score was the sum of 12 domain scores, ranging from 0 (best) to 144 (worst), higher score represented greater frequency and worst severity of the symptoms. NPI-C was an instrument developed on basis of original NPI that gives a score based on product of frequency and severity ratings of 12 symptom domains that were summed to a total score. NPI-C domains: agitation and aggression NPI-C A+A were scored based on both caregiver and participant interviews and score ranged from 0 (does not occur) to 63 (severe). Higher scores indicated more severity.

    Time frame: Baseline (Day 1) and Day 43

  2. Change From Baseline in NPI-C A+A at Day 43: Analyzed Under Estimand 2

    The NPI-12, measure of psychobehavioral disturbances assessed frequency and severity of disturbances in 12 domains, based on a caregiver interview. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being product of frequency and severity scores, such that each domain was scored from 1 to 12. The NPI-12 total score was the sum of 12 domain scores, ranging from 0 (best) to 144 (worst), higher score represented greater frequency and worst severity of the symptoms. NPI-C was an instrument developed on the basis of original NPI that gives a score based on product of frequency and severity ratings of 12 symptom domains that were summed to a total score. NPI-C domains: agitation and aggression NPI-C A+A were scored based on both caregiver and participant interviews and score ranged from 0 (does not occur) to 63 (severe). Higher scores indicated more severity.

    Time frame: Baseline (Day 1) and Day 43

Secondary outcomes

  1. Change From Baseline in Cohen-Mansfield Agitation Inventory- Community Version (CMAI-C) Total Score at Day 43

    The CMAI-C, 37-item scale, measured the ability of a drug to reduce overall frequency of agitation symptoms, including aggressive behaviors. Individual items were rated by the clinician on a scale of 1 (never) to 7 (several times per hour) in which higher score represented the most frequent for each item assessed. CMAI-C total score was a sum of all categories that ranged from 37 (never) to 259 (several times), where higher score indicated greater severity.

    Time frame: Baseline (Day 1) and Day 43

  2. Change From Baseline in Sleep Disorder Inventory (SDI) Average Total Score at Day 43

    SDI: based on caregiver (CG) interview and expanded version of item 11 (night-time behavioral disturbances) of NPI-12. It described frequency, severity and CG burden of sleep-disturbed behaviors for period prior to its administration. It consisted of 7 sub-questions from NPI-12 sleep disturbance item. Each sub-question was made into separate questions with frequency, severity, and CG distress rated with respect to participant. SDI score derived after CG rated frequency, severity of each of 7 separate sleep disturbance symptoms. CG distress ratings were not part of SDI total score, but distress was measured. Frequency scored on scale of 0 (not present) to 4 (once or more per day), severity scored on scale of 0 (not present) to 3 (occurrence of nighttime behaviors) and CG distress rated on scale of 0 (not at all) to 5 (extremely). SDI average total score=average frequency of item 1 to 7 multiplied with average severity of items 1 to 7; ranged from 0 to 12; higher score=greater severity.

    Time frame: Baseline and Day 43

  3. Observed Plasma Concentrations of Seltorexant and Its Metabolite (M12)

    The pharmacokinetic (PK) sample collection was done based on the availability of the participants either on Day 15 or 43 and thus collected data were analyzed and summary data were reported in this outcome measure. Plasma samples were analyzed using liquid chromatography/mass spectrometry/mass spectrometry (LC-MS/MS) method.

    Time frame: Either Day 15 (8 and 14 hours post dose on night of Day 14) or Day 43 (8 and 14 hours post dose on night of Day 42)

07

Results

Posted Nov 25, 2024

Participant flow

Double-blind (DB) Phase (Day 1- Day 43):
Participant flow — Double-blind (DB) Phase (Day 1- Day 43):
MilestoneDB: PlaceboDB: SeltorexantFollow-up (FU): PlaceboFU: Seltorexant
Started444400
Treated424300
Completed393500
Not completed5900
Withdrew: Adverse event0100
Withdrew: Protocol-specified withdrawal criterion met0200
Withdrew: Protocol violation1100
Withdrew: Withdrawal by subject2300
Withdrew: Other0100
Withdrew: Randomized but not treated2100
FU Phase (Day 43 to Day 57):
Participant flow — FU Phase (Day 43 to Day 57):
MilestoneDB: PlaceboDB: SeltorexantFollow-up (FU): PlaceboFU: Seltorexant
Started003938
Completed003934
Not completed0004
Withdrew: Withdrawal by subject0001
Withdrew: Protocol violation0003

Outcome measures

PrimaryChange From Baseline in Neuropsychiatric Inventory Clinician Version (NPI-C) Sum of Agitation and Aggression Domain Scores (NPI-C A+A) at Day 43: Analyzed Under Estimand 1

The NPI-12, measure of psychobehavioral disturbances assessed frequency and severity of disturbances in 12 domains, based on a caregiver interview. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being product of frequency and severity scores, such that each domain was scored from 1 to 12. The NPI-12 total score was the sum of 12 domain scores, ranging from 0 (best) to 144 (worst), higher score represented greater frequency and worst severity of the symptoms. NPI-C was an instrument developed on basis of original NPI that gives a score based on product of frequency and severity ratings of 12 symptom domains that were summed to a total score. NPI-C domains: agitation and aggression NPI-C A+A were scored based on both caregiver and participant interviews and score ranged from 0 (does not occur) to 63 (severe). Higher scores indicated more severity.

Time frame:
Baseline (Day 1) and Day 43
Reported as:
Mean · Score on a scale
Change From Baseline in Neuropsychiatric Inventory Clinician Version (NPI-C) Sum of Agitation and Aggression Domain Scores (NPI-C A+A) at Day 43: Analyzed Under Estimand 1
Score on a scaleDB: PlaceboDB: Seltorexant
Change From Baseline in Neuropsychiatric Inventory Clinician Version (NPI-C) Sum of Agitation and Aggression Domain Scores (NPI-C A+A) at Day 43: Analyzed Under Estimand 1-9.6 ± 8.35-13.4 ± 9.31
Statistical analysis
  • DB: Placebo vs DB: Seltorexant · Mixed model repeated measures · p = 0.308 · Difference of least square (ls) means: -1.5 · 80% CI -3.41 to 0.39
PrimaryChange From Baseline in NPI-C A+A at Day 43: Analyzed Under Estimand 2

The NPI-12, measure of psychobehavioral disturbances assessed frequency and severity of disturbances in 12 domains, based on a caregiver interview. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being product of frequency and severity scores, such that each domain was scored from 1 to 12. The NPI-12 total score was the sum of 12 domain scores, ranging from 0 (best) to 144 (worst), higher score represented greater frequency and worst severity of the symptoms. NPI-C was an instrument developed on the basis of original NPI that gives a score based on product of frequency and severity ratings of 12 symptom domains that were summed to a total score. NPI-C domains: agitation and aggression NPI-C A+A were scored based on both caregiver and participant interviews and score ranged from 0 (does not occur) to 63 (severe). Higher scores indicated more severity.

Time frame:
Baseline (Day 1) and Day 43
Reported as:
Mean · Score on a scale
Change From Baseline in NPI-C A+A at Day 43: Analyzed Under Estimand 2
Score on a scaleDB: PlaceboDB: Seltorexant
Change From Baseline in NPI-C A+A at Day 43: Analyzed Under Estimand 2-9.6 ± 8.25-13.4 ± 9.31
Statistical analysis
  • DB: Placebo vs DB: Seltorexant · Mixed model repeated measures · p = 0.282 · Difference of least square (ls) means: -1.5 · 80% CI -3.33 to 0.29
SecondaryChange From Baseline in Cohen-Mansfield Agitation Inventory- Community Version (CMAI-C) Total Score at Day 43

The CMAI-C, 37-item scale, measured the ability of a drug to reduce overall frequency of agitation symptoms, including aggressive behaviors. Individual items were rated by the clinician on a scale of 1 (never) to 7 (several times per hour) in which higher score represented the most frequent for each item assessed. CMAI-C total score was a sum of all categories that ranged from 37 (never) to 259 (several times), where higher score indicated greater severity.

Time frame:
Baseline (Day 1) and Day 43
Reported as:
Mean · Score on a scale
Change From Baseline in Cohen-Mansfield Agitation Inventory- Community Version (CMAI-C) Total Score at Day 43
Score on a scaleDB: PlaceboDB: Seltorexant
Change From Baseline in Cohen-Mansfield Agitation Inventory- Community Version (CMAI-C) Total Score at Day 43-17.5 ± 18.67-20.3 ± 21.69
SecondaryChange From Baseline in Sleep Disorder Inventory (SDI) Average Total Score at Day 43

SDI: based on caregiver (CG) interview and expanded version of item 11 (night-time behavioral disturbances) of NPI-12. It described frequency, severity and CG burden of sleep-disturbed behaviors for period prior to its administration. It consisted of 7 sub-questions from NPI-12 sleep disturbance item. Each sub-question was made into separate questions with frequency, severity, and CG distress rated with respect to participant. SDI score derived after CG rated frequency, severity of each of 7 separate sleep disturbance symptoms. CG distress ratings were not part of SDI total score, but distress was measured. Frequency scored on scale of 0 (not present) to 4 (once or more per day), severity scored on scale of 0 (not present) to 3 (occurrence of nighttime behaviors) and CG distress rated on scale of 0 (not at all) to 5 (extremely). SDI average total score=average frequency of item 1 to 7 multiplied with average severity of items 1 to 7; ranged from 0 to 12; higher score=greater severity.

Time frame:
Baseline and Day 43
Reported as:
Mean · Score on a scale
Change From Baseline in Sleep Disorder Inventory (SDI) Average Total Score at Day 43
Score on a scaleDB: PlaceboDB: Seltorexant
Change From Baseline in Sleep Disorder Inventory (SDI) Average Total Score at Day 43-0.8 ± 1.02-0.5 ± 0.90
SecondaryObserved Plasma Concentrations of Seltorexant and Its Metabolite (M12)

The pharmacokinetic (PK) sample collection was done based on the availability of the participants either on Day 15 or 43 and thus collected data were analyzed and summary data were reported in this outcome measure. Plasma samples were analyzed using liquid chromatography/mass spectrometry/mass spectrometry (LC-MS/MS) method.

Time frame:
Either Day 15 (8 and 14 hours post dose on night of Day 14) or Day 43 (8 and 14 hours post dose on night of Day 42)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Observed Plasma Concentrations of Seltorexant and Its Metabolite (M12)
nanograms per milliliter (ng/mL)DB: Seltorexant
Total Seltorexant121 ± 156
Total M12141 ± 164

Adverse events

Collected over Double-blind (DB) Phase: From Day 1 up to Day 43; Follow up Phase: From Day 44 to Day 57. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB: Placebo0/44 (0%)0/42 (0%)4/42 (9.5%)
DB: Seltorexant0/44 (0%)1/43 (2.3%)6/43 (14%)
Follow-up (FU): Placebo0/39 (0%)0/39 (0%)0/39 (0%)
FU: Seltorexant0/38 (0%)1/38 (2.6%)2/38 (5.3%)
Most frequent serious events
Most frequent serious events
EventDB: PlaceboDB: SeltorexantFollow-up (FU): PlaceboFU: Seltorexant
Pancreatic Neuroendocrine TumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/420/430/391/38
Ischaemic StrokeNervous system disorders0/421/430/390/38
Most frequent other events
Showing 10 of 17
Most frequent other events
EventDB: PlaceboDB: SeltorexantFollow-up (FU): PlaceboFU: Seltorexant
Malignant Biliary ObstructionHepatobiliary disorders0/420/430/391/38
OrchitisInfections and infestations0/420/430/391/38
Neck PainMusculoskeletal and connective tissue disorders0/420/430/391/38
Tension HeadacheNervous system disorders0/420/430/391/38
PruritusSkin and subcutaneous tissue disorders0/420/430/391/38
NasopharyngitisInfections and infestations1/421/430/390/38
ContusionInjury, poisoning and procedural complications1/420/430/390/38
InjuryInjury, poisoning and procedural complications1/420/430/390/38
HeadacheNervous system disorders1/420/430/390/38
CoughRespiratory, thoracic and mediastinal disorders1/420/430/390/38

Baseline characteristics

Full analysis set included all randomized participants who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(years)DB: PlaceboDB: SeltorexantTotal
Mean72.6 ± 7.7573.4 ± 6.1873 ± 6.97
Age, Customized
Age, Customized(Participants)DB: PlaceboDB: SeltorexantTotal
Adults (18-64 years)729
From 65 to 84 years354075
85 years and over011
Sex: Female, Male
Sex: Female, Male(Participants)DB: PlaceboDB: SeltorexantTotal
Female262854
Male161531
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DB: PlaceboDB: SeltorexantTotal
Hispanic or Latino394382
Not Hispanic or Latino303
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DB: PlaceboDB: SeltorexantTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American325
White374178
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)DB: PlaceboDB: SeltorexantTotal
UNITED STATES424385
Age Categorical
Age Categorical(Participants)DB: PlaceboDB: SeltorexantTotal
Adults (18-64 years)729
From 65 to 84 years354075
85 years and over011
08

Study locations

25 sites
  • Medical Advancement Center of Arizona
    Tempe, Arizona 85283, United States
  • Sunwise Clinical Research
    Lafayette, California 94549, United States
  • Luminous Clinical Research
    Homestead, Florida 33030, United States
  • South Florida Research Center Inc.
    Miami Springs, Florida 33166, United States
  • Global Medical Institutes
    Miami, Florida 33125, United States
  • Office of Emilio Mantero-Atienza, MD
    Miami, Florida 33135, United States
  • Allied Biomedical Research Institute (ABRI), Inc
    Miami, Florida 33155-4630, United States
  • Quantix Research
    Miami, Florida 33155, United States
  • Entrust Clinical Research
    Miami, Florida 33156, United States
  • Florida International Research Center (FIRC)
    Miami, Florida 33173, United States
  • P&S Research, LLC
    Miami, Florida 33175, United States
  • IMIC Inc
    Miami, Florida 33176, United States
  • Biovision Medical
    Miami, Florida 33184, United States
  • Intercoastal Medical Group
    Sarasota, Florida 34239, United States
  • Accel Clinical Research
    Seminole, Florida 33777, United States
  • Sonar Clinical Research
    Atlanta, Georgia 30315, United States
  • NeuroTrials Research Inc
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Gill Neuroscience
    Cypress, Texas 77429, United States
  • Wasatch Clinical Research
    Salt Lake City, Utah 84107, United States
  • Memory Clinic Inc
    Bennington, Vermont 05201, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Nov 2023, 17 months.

Results were first posted in Nov 2024, 1 year after primary completion.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 17 months is below that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
Apr 1, 2022
StartActual
May 19, 2022
Primary completionActual
Nov 10, 2023
CompletionActual
Nov 10, 2023
Results first posted
Nov 25, 2024
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05307692
Responsible party
Sponsor
First posted
Apr 1, 2022
Start date
May 19, 2022
Primary completion
Nov 10, 2023
Completion
Nov 10, 2023
Results posted
Nov 25, 2024
Last update
Apr 27, 2025

Study contacts

Janssen Research and Development, LLC Clinical Trial
study director · Janssen Research and Development LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion